debt_leverage_profile
6.11x Total Debt / Equity (High leverage)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; pre-revenue biotech with minimal debt, funded by equity raises; rising rates increase cost of future capital raises
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Peptide/antigen synthesis suppliers (likely US/EU-based CMOs) and adjuvant raw material sourcing from limited specialty chemical producers
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; clinical-stage US-focused company with negligible foreign currency exposure
Inferred
Agent_Inference
geographic_footprint
Essentially zero sovereign currency devaluation risk; all operations and trials US-based with USD-denominated expenses
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single or dual CMO partners for amphiphilic peptide-antigen conjugate manufacturing; non-substitutable in short term
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; no cloud-revenue dependency; AWS/GCP termination would disrupt operations modestly but not existentially
Inferred
Agent_Inference
business_model_type_secondary
Research and pipeline development model; secondary reliance on bioinformatics platforms and CRO data systems potentially cloud-hosted
Inferred
Agent_Inference
switching_cost_profile
Moderate API/platform coupling risk via genomic databases and CRO software; switching costs manageable but time-consuming during active trials
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is milestone/royalty from pharma partnerships and eventual drug sales, not investment contracts
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low GDPR/CCPA exposure; limited patient data handled directly; clinical trial data governed by FDA/IRB frameworks, not primarily GDPR
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; niche lymph-node targeting cancer vaccine platform with no dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/milestone-based; no recurring subscription revenue; dependent on partnership deals and future product commercialization
Inferred
Agent_Inference
monetization_vector
Partnership licensing milestones and eventual drug royalties/sales; currently pre-revenue with NIH grants and collaboration agreements
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future oncology drug pricing will follow specialty biologics model, likely $50K–$200K+ per treatment course
Inferred
Agent_Inference
pricing_power_rating
Potentially high if AMP platform demonstrates superior efficacy; oncology drugs with novel MOA command premium pricing with limited payer pushback
Inferred
Agent_Inference
target_gross_margin_bracket
Expected 70–85% gross margin at commercialization, consistent with biologic drug manufacturers post-COGS normalization
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; platform is proprietary and patent-protected; clinical partnerships require formal agreements
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth expected; R&D-heavy now but commercial scaling would leverage CMO/CRO outsourcing, limiting headcount proportionality
Inferred
Agent_Inference
marginal_cost_of_growth
Low marginal cost per additional indication if AMP platform is modular; pipeline expansion leverages existing IP without proportional spend
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics unclear; partnership-driven model means few large deals dominate; sales force needs modest scaling
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value is IP and clinical data-driven, not user-base dependent
Inferred
Agent_Inference
asset_efficiency_ratio
-153.0% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; oncology drugs face inelastic demand but biotech funding and partnership deals are cyclically sensitive
Inferred
Agent_Inference
customer_segment_primary
Biopharmaceutical partners and licensees seeking cancer vaccine/immunotherapy platform access; highly concentrated, few large deals
Inferred
Agent_Inference
customer_segment_secondary
Government and non-profit grant funders (NIH, NCI); secondary revenue source with concentration risk in federal budget cycles
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.7% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001601485
High
SEC-EDGAR
ticker
ELTX
High
SEC-EDGAR